A Multicenter, Seamless, Randomized, Third-Party-Blind, Clinical Trial to Evaluate the Safety and Efficacy of Meplazumab in Addition to Standard of Care for the Treatment of COVID-19 in Hospitalized Adults
Latest Information Update: 19 Sep 2023
At a glance
- Drugs Meplazumab (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- Sponsors Pacific Meinuoke Biopharmaceutical
- 14 Sep 2023 Status changed from recruiting to completed.
- 17 Mar 2022 Planned End Date changed from 30 Jul 2022 to 30 Sep 2023.
- 17 Mar 2022 Planned primary completion date changed from 31 May 2022 to 30 Jun 2023.